CFIUS Clearance: DiaSorin S.p.A. and Luminex Corporation

Status: CFIUS Clearance

Acquirer: DiaSorin S.p.A. (Italy)

Acquired: Luminex Corporation (U.S.)

Value: $1.8 billion

Industry Tags: Medical Device & Equipment; Biotechnology; Life Sciences

On April 11, 2021, DiaSorin S.p.A., an Italian publicly traded company (FTSE MIB: DIA) that is a “global leader in the In Vitro Diagnostic (IVD) field,” announced that its Board of Directors approved a merger agreement to acquire Luminex Corporation, a publicly traded (NASDAQ: LMNX) company that “develops, manufactures and sells proprietary biological testing technologies and products,” and that is “a leader in multiplexing technology . . .” (Luminex Corporation Schedule 14A, Apr. 12, 2021, SEC Filing.) “The transaction is expected to close within the third quarter of 2021 and is subject to Luminex shareholder approval and to other customary closing conditions, including the satisfaction of antitrust and CFIUS regulatory requirements.” (Id.)  On July 8, 2021, the parties “received approval from the Committee on Foreign Investment in the United States . . .”  (Luminex Corporation Form 8-K, July 9, 2021, SEC Filing.)

Please contact us with any questions.